Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic a...
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
About this item
Full title
Author / Creator
Publisher
England: EULAR
Journal title
Language
English
Formats
Publication information
Publisher
England: EULAR
Subjects
More information
Scope and Contents
Contents
ObjectiveTo review long-term certolizumab pegol (CZP) safety across all approved indications: rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD).MethodsData were pooled across 49 UCB-sponsored CZP clinical trials (27 RA, one axSpA, one PsA, five PSO, 15 CD) to August 2017....
Alternative Titles
Full title
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4c136ee3aa604414844a71e47a3e4a70
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4c136ee3aa604414844a71e47a3e4a70
Other Identifiers
ISSN
2056-5933
E-ISSN
2056-5933
DOI
10.1136/rmdopen-2019-000942
